Physician profile
Ryan Zaidinski
NPI 1255952669
$1,471.42
in general payments reported to CMS, 2019-2025
8 companies · $657 in 2025
The $657 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.99 · 2022: $139 · 2023: $116 · 2024: $537 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214 · Entertainment: $95.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.96 |
| Entertainment | $95.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $630.68 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $492.40 | 2024-2025 | Clariti Contact Lens, Misight Contact Lens, Myday Contact Lens |
| Lkc Technologies, INC. | $120.14 | 2025 | |
| Optos, INC. | $95.91 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $52.65 | 2022-2023 | Clareon, Precision 1 |
| Abb Con-Cise Optical Group LLC | $34.31 | 2024 | Spectacle Lenses, Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.99 | 2021 | |
| Dompe US, INC. | $22.34 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Zaidinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.